 |
BioWorld-International-2008-07-30
Lateral Thinking Aims to Exploit Benefits of Drug Side Effects
Genomic Vision Raises €4M in its Series B Financing
No Abstract
BioWorld International Correspondent
PARIS - Genomic Vision, which is developing new diagnostic tools and therapeutics in the areas of cancer and acute genetic and viral diseases, completed a series B financing in which it raised €4 million (US$6.3 million).
TauRx Shows Strong Results Slowing Alzheimer's Progress
LONDON - TauRx Therapeutics Ltd. presented positive data on the first tau inhibitor to complete Phase II in the treatment of Alzheimer's disease, showing the drug, rember, slowed the progress of the mild to moderate form of the disorder by 81 percent over 12 months. (BioWorld International)